Ocugen, Inc.

NASDAQ:OCGN

Biotechnology

Healthcare
$0.74 +2.46%

+$0.03 today

Market cap
$250.82M
Beta
2.21
P/E (TTM)
-5.6
EPS (TTM)
-$0.22
52W Low $0.90High $2.73

Volume 5.83M

Average 7.51M

OCGN Operating Cash Flow

Cash generated by the company's core business operations during the period.

Ocugen, Inc.NASDAQ: OCGN

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow grows, but more slowly than its trailing trend

Q1 FY2026 operating cash flow of $21.79M (cash outflow) rose 12.6% year over year, behind the +16.7% change in trailing-twelve-month operating cash flow. Sequentially, it rose 56.1% from the prior quarter. Over 3 fiscal years it compounded at -1.8% a year.

Context

  • Operating cash flow amounted to 1290.8% of revenue in FY2025, up 251.6 pp from a year earlier.
  • Operating cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +12.6% toward the trailing-twelve-month pace of +16.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21.79M+56.1% QoQ
Last fiscal yearDec 2025
-$56.96M+35.2% YoY
LTMMar 2026
-$59.4M+16.7% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.6%——
1 year+35.2%——
3-year CAGR-1.8%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(56.96M) USD
Year-over-year change
-35.2%

Operating Cash Flow vs competitors

How OCGN compares with its peers on the latest reported figures

  • OCGN's LTM Mar 2026 operating cash flow of $59.4M is the 7th largest of the 10 companies compared; the peer median is $81.94M.
  • Its year-over-year change of +16.7% is the 3rd highest of 10, against a peer median of -3.0%.
  • Operating cash flow amounts to 1330.4% of revenue for OCGN, versus a peer median of 149.6%.
OCGN Competitors Peer median
Operating Cash Flow for OCGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$351.4M +1.8%+50.8%4749.9%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$193.4M -3.0%+21.6%—
ADCTADC Therapeutics S.A.LTM Mar 2026$114.55M -15.8%+0.7%144.7%
OMEROmeros CorporationLTM Mar 2026$94.76M -33.7%+10.3%957.8%
NGNENeurogene Inc.LTM Mar 2026$81.94M +17.5%+13.5%—
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$63.56M -913.9%-14.8%—
OCGNOcugen, Inc.LTM Mar 2026$59.4M +16.7%-1.8%1330.4%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$53.2M +20.4%+12.9%—
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$38.8M -76.8%-8.6%55.7%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$22.11M -0.4%—149.6%
Peer median (excluding OCGN) $81.94M-3.0%+11.6%149.6%

Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.37M)(86.8M)(63.08M)(54.05M)(67.85M)
Depreciation & Amortization229K480K704K1.97M2.39M
Deferred Income Tax(52K)0000
Stock-Based Compensation6.96M10.54M9.22M7.43M7.71M
Change in Working Capital2.49M9.2M(13.16M)3.67M(523K)
Accounts Receivables00000
Inventory00000
Accounts Payables3.5M0000
Other Working Capital(1.01M)9.2M(13.16M)3.67M(523K)
Other Non-Cash Items799K6.51M4.26M(1.15M)1.31M
Operating Cash Flow(47.94M)(60.08M)(62.05M)(42.14M)(56.96M)
Capital Expenditures(939K)(4.46M)(10.48M)(3.39M)(185K)
Acquisitions (Net)00000
Purchases of Investments0(13.27M)(3.95M)00
Sales of Investments0017.5M00
Other Investing Activities(877K)761K00(126K)
Investing Cash Flow(1.82M)(16.97M)3.08M(3.39M)(311K)
Debt Repayment(10K)500K500K30M(1M)
Common Stock Issued129.21M59.57M20.8M38.56M18.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(8.53M)(592K)(68K)(3.7M)0
Financing Cash Flow120.68M59.48M20.88M64.86M17.33M
Effect of Forex Changes(325)25K(5K)28K13K
Net Change in Cash70.92M(17.55M)(38.1M)19.36M(39.93M)
Free Cash Flow(48.88M)(64.54M)(72.53M)(45.53M)(57.15M)

Ocugen, Inc.

NASDAQ:OCGN

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.